A team of investigators from McLean Hospital and Harvard Medical School, led by Kai C. Sonntag, MD, PhD, and Bruce M. Cohen, MD, PhD, has found a connection between disrupted energy production and the development of late-onset Alzheimer’s disease (LOAD). The findings appear in the current issue of Scientific Reports. “These findings have several implications for...
Tag: <span>Alzheimer’s disease</span>
Post
Research consortium LipiDiDiet finds a way to impact Alzheimer’s disease before it’s too late
Professor Tobias Hartmann, Saarland University in Germany. The pioneering clinical trial is part of a large European Union funded project and involved 311 patients across 11 sites in four countries (Finland, Germany, the Netherlands and Sweden). The trial involved patients with prodromal Alzheimer’s (often referred to as Mild Cognitive Impairment or MCI). Patients were...
Post
Delayed word processing could predict patients’ potential to develop Alzheimer’s disease
Diagram of the brain of a person with Alzheimer’s Disease. A delayed neurological response to processing the written word could be an indicator that a patient with mild memory problems is at an increased risk of developing Alzheimer’s disease, research led by the University of Birmingham has discovered. Using an electroencephalogram (EEG) – a...
Post
One step closer toward a treatment for Alzheimer’s disease?
Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid Scientists at the Massachusetts General Hospital (MGH), in collaboration with colleagues at the University California, San Diego (UCSD), have characterized a new class of drugs as potential therapeutics for Alzheimer’s disease and discovered a piece in the puzzle of how they would...
Post
New ‘plaque destroying’ light therapy could prevent Alzheimer’s disease by blitzing dangerous proteins
Researchers from Rice University in Houston, Texas, developed a probe to target proteins in the brain that cause Alzheimer’s disease More than five million people in the US suffer from the degenerative disease Previous studies have used medication to attempt to target these proteins Experts say this probe could improve medication for the disease Rogue...
Post
‘Ideal biomarker’ detects Alzheimer’s disease before the onset of symptoms
Croatia, New Mexico (October, 2017): Absence of a prefrontal activation during sensory gating of simple tones detects the Alzheimer’s disease (AD) before the occurrence of the first symptoms. Sanja Josef Golubic Ph.D., physicists at the Department of Physics, Faculty of Science, University of Zagreb, reveals the high potential, absolutely non-invasive biomarker of AD pathology in...
Post
Experimental brain technology can rewind Alzheimer’s disease
Alzheimer’s disease is considered a global challenge of the century. Alzheimer’s disease is a thief. It comes and takes away the most precious memories with which people identify themselves. It is a very clever thief. People whom it affects don’t even remember what they have lost—they just feel lost; lost in space and time. Alzheimer’s can...
Post
Do Microbes Trigger Alzheimer’s Disease?
In late 2011, Drexel University dermatology professor Herbert Allen was astounded to read a new research paper documenting the presence of long, corkscrew-shape bacteria called spirochetes in postmortem brains of patients with Alzheimer’s disease.1 Combing data from published reports, the International Alzheimer Research Center’s Judith Miklossy and colleagues had found evidence of spirochetes in 451 of 495 Alzheimer’s brains....
Post
Stabilizing TREM2, a potential strategy to combat Alzheimer’s disease
Uncovering the molecular mechanism behind a rare genetic risk factor of Alzheimer’s disease points to a new therapeutic target A gene called triggering receptor expressed on myeloid cells 2, or TREM2, has been associated with numerous neurodegenerative diseases, such as Alzheimer’s disease, Frontotemporal lobar degeneration, Parkinson’s disease, and Nasu-Hakola disease. Recently, a rare mutation in...
Post
Physicist reports binary marker of preclinical and clinical Alzheimer’s disease
A new technique shows high potential for providing a discrete, non-invasive biomarker of Alzheimer’s disease (AD) at the individual level during both preclinical and clinical stages. The proposed biomarker has a large effect size (0.9) and high accuracy, sensitivity and specificity (100 percent) in identifying symptomatic AD patients within a research sample, according to Sanja...